Verfahren zur Verkapselung von Mycobacterium Bovis Bcg-Impfstoffbakterien in einem Alginatträger zur Bekämpfung einer Helicobacter Pylori-Infektion

Details

Veröffentlichungs-Nr.

EP4817599

Anmeldetag

19. März 2026

Veröffentlichung

7. Oktober 2026

Rechtsraum

EP

Abstract

The invention relates to a method of manufacturing microparticles containing Mycobacterium bovis BCG vaccine bacilli encapsulated in an alginate carrier, intended for combating Helicobacter pylori infection, characterised in that an aqueous solution of a non-ionic copolymeric surfactant (C₃H₆O.C₂H₄O)_X and/or a solution of chitosan in 1% acetic acid, and a suspension of live M. bovis BCG in 1 mL of saline solution with a BCG density of 3×10⁹ CFU/mL, and then subjected to a microencapsulation procedure by adding the above-mentioned solutions dropwise, using a 2 mL syringe, to a vessel containing a 0.5% calcium chloride solution, at room temperature on a magnetic stirrer for 1 hour. After one hour, the microcapsules are drained using a laboratory sieve and rinsed with sterile distilled water, using chitosans with a molecular weight in the range of 50.000-190.000 g/mol or 190.000-310.000 g/mol or 310.000-375.000 g/mol, with the concentration of the polymer solution used to prepare the alginate microcapsules being 2% v/v for alginate, 1% v/v for chitosan and 12 600 g/mol for the non-ionic copolymer surfactant (C₃H₆O.C₂H₄O)x.

Anmelder

Firmen

Uniwersytet Lodzki
Centrum Badan Molekularnych i Makromolekularnych Polskiej Akademii Nauk z siedziba w Lodzi

Land

🇵🇱 Polen